GC Biopharma, a biotechnology pioneer in South Korea, is now preparing to take another major leap forward toward ensuring a healthier and happier future for all peoples worldwide. Challenge and innovation, care and compassion, transparency and integrity, and respect and dedication are the core principles that guide GC Biopharma on its journey toward achieving its next goal.

Our mission is to usher in a healthier and happier future for all humankind. To this end, GC Biopharma has been engaging in a wide range of pharmaceutical research and development over the last five decades.
A healthier, happier life is what we are committed to providing for patients, medical practitioners, and people around the world.

Varicella Vaccine

BARYCELA (varicella II vaccine), is the world’s only antibiotic-free varicella vaccine, obtained domestic approval in 2020, and an application for WHO PQ has been submitted and is currently under review. The company expects the BARYCELA, to help the company expand its presence on the global vaccine market.

Seasonal Influenza Vaccine

GCFLU Quadrivalent (prefilled syringes), immunizing against one more strain of influenza virus subtype B in addition to the two strains of subtype A and another strain of subtype B, was the first of its kind to win government approval in Korea and the fourth in the world to win WHO approval in 2015.